How biotech startups are funded, from seed round to IPO
Grants, angels, venture rounds, partnerships, IPOs and the less familiar routes in between, and what each one costs a founder in ownership.
Graham Eckert
Graham spent years reading biotech pipelines and company filings as an industry analyst. He writes about how drugs and cell therapies are developed, manufactured and paid for, with the numbers and the caveats left in.
Pieces by Graham
Why most drugs fail between phase 2 and approval
Phase 2 is where most experimental drugs stop. The numbers behind that, the main reasons, and what they mean when you read trial news.
How a cell therapy is made, from donor to dose
A tablet factory can press millions of identical doses from one batch of powder. Many cell therapies work the other way around: one batch, one patient, made…